Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rabeprazole Safety and Efficacy in Adolescents with GERD
NCT00132496Phase 2Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Aug 2005
- Primary completion
- May 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of rabeprazole in gastroesophageal reflux disease (GERD) (2 arms), sponsored by Eisai Co., Ltd. Primary endpoint: Treatment-emergent Adverse Events at 8 weeks. Started Aug 2005; status: completed.
02
Drugs
rabeprazole
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NCT00132496.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00132496.